MRNAModerna, Inc.

Nasdaq modernatx.com


$ 148.18 $ 0.02 (0.02 %)    

Tuesday, 11-Jun-2024 15:38:38 EDT
QQQ $ 466.99 $ 3.49 (0.75 %)
DIA $ 387.42 $ 0.05 (0.01 %)
SPY $ 536.16 $ 2.08 (0.39 %)
TLT $ 91.81 $ 0.76 (0.83 %)
GLD $ 214.01 $ -0.41 (-0.19 %)
$ 148.59
$ 148.15
$ 148.03 x 200
$ 160.00 x 185
$ 147.12 - $ 150.45
$ 62.55 - $ 170.47
5,969,563
na
56.76B
$ 0.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 10-30-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-13-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

- Reuters Citing Goldman Sachs Conference

 whats-going-on-with-moderna-stock-monday

Moderna said its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, met its pri...

 nike-merck-general-motors-and-more-cnbcs-final-trades

Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of ...

 moderna-seeks-fda-approval-for-updated-covid-19-shot-for-upcoming-season

Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1.

Core News & Articles

- Reuters

 moderna-submits-application-to-fda-for-review-of-spikevax-2024-2025-formula-targeting-sars-cov-2-variant-jn1

https://www.accesswire.com/872882/moderna-initiates-submission-to-fda-of-jn1-targeting-covid-19-vaccine

 first-human-death-from-bird-flu-strain-puts-vaccine-stocks-back-on-the-map

Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month.

 fda-selects-modernas-rare-disease-candidate-for-accelerated-development-program

Moderna's mRNA-370 has been selected for the FDA's START program to accelerate rare disease therapeutics, targeting a 2...

Core News & Articles

- Bloomberg

Core News & Articles

https://globalnews.ca/news/10547712/bird-flu-death-mexico-h5n2/#:~:text=It%20started%20on%20April%2017,to%20complications%20of%...

 sp-500-nasdaq-100-jointly-hit-all-time-highs-nvidia-overtakes-apple-as-second-most-valuable-us-company

The S&P 500 and Nasdaq 100 indices closed at record highs due to investor confidence in AI-driven tech sector growth. Magni...

Core News & Articles

- Bloomberg

Core News & Articles

- Reuters

 whats-going-on-with-novavax-stock

Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look...

 moderna-says-it-is-prepared-to-submit-for-approval-a-covid-vaccine-targeting-either-jn1-or-kp2-variant

- Reuters

 promising-trial-results-show-new-standards-in-cancer-treatment-and-diagnostics-are-on-the-horizon

On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a...